Identifying mechanisms of tumor response and resistance to immunotherapy

Immunotherapies have revolutionized cancer treatment by offering long-term remission to patients with previously uncurable disease. However, resistance to immunotherapy remains a major problem for patients, with more than 80% of all cancer patients not responding. The Miller lab is working to improve the efficacy of immunotherapy by dissecting immune cells found in resistant tumors. We are particularly interested in myeloid cells, a poorly understood group of immune cells that regulate nearly all aspects of the immune response. 

Using patient samples, mouse models, single-cell profiling, and functional genomics approaches, we are working to identify novel myeloid-directed therapies that allow us to overcome resistance and successfully treat more patients.